



Press Release

ender diagnostics and SWISS collaborate to test cabin crew for COVID-19

- ender diagnostics to provide SARS-CoV-2 testing for all SWISS long-haul cabin crew
- SWISS is firmly committed to maintaining the highest standards of protection to keep its customers' air travel as safe as possible
- US FDA clearance for ender MASS, enabling on-site and pop-up labs to operate rapid testing for COVID-19, anticipated in September 2020

Bern, Switzerland, 3 September 2020 – **ender diagnostics, a Swiss company specializing in the development of rapid molecular biological tests, today announced a collaboration with Swiss International Air Lines (SWISS), a subsidiary of Lufthansa AG, to test all long-haul cabin crew members for SARS-CoV-2, the virus which causes COVID-19.**

Constant rapid and flexible testing is the key to controlling the coronavirus pandemic. Testing SWISS long-haul crew members prior to departure working with ender diagnostics will help to further improve detection of COVID-19 infection, increasing the safety and confidence of people traveling.

Martin Knuchel, Head of Crisis, Emergency & Business Continuity Management Lufthansa Group Airlines and Pandemic Coordinator, commented: «The safety and confidence of our passengers and employees is paramount for SWISS. The decision to adopt the fast, innovative and easy-to-use testing solutions developed by ender diagnostics further underlines our absolute commitment to make air travel as safe as possible.»

ender diagnostics specializes in isothermal PCR*-based test kits for laboratory and on-site diagnosis. It has launched two CE-marked tests in Europe: ender LAB in June and ender MASS in August 2020. The ender LAB test allows laboratories to directly detect SARS-CoV-2 on standard real-time PCR devices within 30 minutes of extraction of the viral RNA. This is significantly faster than commercially available PCR tests, which take several hours. ender MASS offers additional benefits by enabling detection in a simplified process, considerably reducing the workload for medical professionals and laboratories. It is designed to enable on-site and pop-up labs to operate rapid testing in diverse settings, including travel-related locations such as airports and cruise ships.

Hans-Peter Frank, Chief Business Officer of ender diagnostics, said: «With simplified workflows and analysis, our products can process up to eight times as many tests as conventional PCR test over the same period. This significantly increases both test capacity and flexibility in laboratories and is a promising step towards mass screening. We are pleased to be able to support SWISS in their efforts to protect their passengers and employees.»

For media inquiries, please contact:

media@enderdiagnostics.com

or Beatrix Benz, Communications Manager, b.benz@enderdiagnostics.com; +41 79 256 77 73

For more information about ender diagnostics' products, please contact:

info@enderdiagnostics.com

or Hans-Peter Frank, Chief Business Officer, hp.frank@enderdiagnostics.com; +41 79 743 27 77

About ender diagnostics

ender diagnostics is a private company headquartered in Bern, Switzerland, and with US offices in Miami. ender diagnostics focuses on the development of rapid molecular tests for the detection of SARS-CoV-2. The ender team has extensive experience in developing molecular biological rapid tests for infectious diseases. The company is supported by several private investors with know-how and financing. <https://enderdiagnostics.com/>